methylcobalamin
Methylcobalamin (also known as mecobalamin, MeCbl, or MeB12) is one of the two forms of biologically active vitamin B12. Methyl-B12 is the principal form of circulating vitamin B12, hence the form, which is transported into peripheral tissue. Methylcobalamin is absorbed by the intestine by a specific mechanism, which uses the intrinsic factor, and by a diffusion process in which approximately 1% of the ingested dose is absorbed. Cyanocobalamin and hydroxycobalamin are forms of the vitamin that require conversion to methylcobalamin. Methylcobalamin alone or in combination with others compound are used to treat different diseases. Being a component of CEREFOLIN NAC it is used to treat Alzheimer's dementia. As a part of METANX® tablets is used for the dietary management of endothelial dysfunction in patients with diabetic peripheral neuropathy. Methylcobalamin exerted therapeutic effects on neuropathic pain in diabetics, possibly through its neurosynthesis and neuroprotective actions. The possible mechanisms can be considered as follows. (1) Methylcobalamin improved nerve conduction velocity; (2) methylcobalamin promoted injured nerve regeneration, recovering the neuromuscular functions in peripheral hyperalgesia and allodynia; and (3) methylcobalamin inhibited the ectopic spontaneous discharges from peripheral primary sensory neurons in neuropathic pain states. Methylcobalamin is the only form that can cross the blood-brain barrier and so can directly protect brain cells from degeneration. While crossing the barrier, it also stimulates production of serotonin, a chemical neurotransmitter responsible for elevated mood; research where Alzheimer’s patients were administered methylcobalamin showcased improvements in memory, communication skills, and emotions. It also helps form the myelin sheath, the insular coating around nerve cells that allow for electrical impulses to travel through the nervous system more efficiently. — NCATS
Clinical trial activity
22 trials · 41 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2008 (NCT00710359)
Timeline
Indications
Approved for
Studied for
- Amyotrophic Lateral Sclerosis · Phase 3
- Autistic Disorder · Phase 2/Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Colorectal Neoplasms · Phase 1
- Diabetic Neuropathies · Phase 2
- Healthy Volunteers · Phase 1
- Hypertension, Renal · Phase 4
- Kidney Failure, Chronic · Phase 4
- Mutation · Phase 2
- Peripheral Nervous System Diseases · Phase 4
- Small Cell Lung Carcinoma · Phase 3
Mechanism of action
- UnclearSupplementation
Unclear supplementation
Chemistry & pharmacology
SMILES
[CH3-].[Co+3].C[C@@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N-]C1=C(C)C3=NC(=CC4=NC(=C(C)C5=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O)OP([O-])(=O)O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)N7C=NC8=C7C=C(C)C(C)=C8- Mol. weight
- 1344.3823 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMethylcobalamin ↗
- NCATSBR1SN1JS2W ↗
Also known as
- adenosylcobalamin
- cobalamin coenzyme
- cobamamide
- cobamamide
- cobamamide
- methyl b12
- methyl b12
- vitamin b12 coenzyme
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06990854 | N/A | Jul 1, 2025 | Hangzhou Third Hospital, Zhejiang Chinese Medical University |
| NCT05785585 | N/A | Sep 9, 2023 | Eurecat, Laboratorio Echevarne |
| NCT05751187 | Phase 2 | Jun 27, 2023 | Jiao Tong University, Merck |
| NCT05807711 | Phase 4 | Apr 1, 2023 | Alexandria University |
| NCT04786964 | Phase 3 | Sep 30, 2021 | Fortress Biotech |
| NCT04265534 | Phase 2 | Apr 30, 2020 | Calithera Biosciences |
| NCT03898336 | N/A | Jul 1, 2019 | Radboud University, University of Groningen, University of Heidelberg |
| NCT03885882 | Phase 1 | Apr 13, 2019 | Eisai |
| NCT03783104 | N/A | Feb 1, 2019 | Paropakar Maternity and Women's Hospital, Sitaram Bhartia Institute of Science and Research, University of London |
| NCT03485404 | N/A | Sep 30, 2018 | Anhui Medical University, Huazhong University of Science and Technology, Jiao Tong University, Nanjing University, People's Liberation Army of China, Shaanxi Provincial People's Hospital, Xijing Hospital |
| NCT03626922 | Phase 1 | Aug 31, 2018 | Eli Lilly, Merck, NSABP Foundation |
| NCT03406793 | N/A | Feb 20, 2018 | International Center for Diarrheal Disease Research, Johns Hopkins University, University of California, San Francisco, University of Colorado, Denver |
| NCT04706377 | N/A | Feb 1, 2018 | Aristotle University of Thessaloniki, Sheffield Hallam University, University of Tuebingen |
| NCT03825042 | N/A | Jan 23, 2018 | Menarini Group |
| NCT04372316 | Phase 2 | Dec 25, 2017 | Peking University |
| NCT03909789 | N/A | Nov 17, 2017 | Los Angeles Biomedical Research Institute |
| NCT03548311 | Phase 3 | Nov 1, 2017 | Eisai, University of Tokushima |
| NCT03950674 | Phase 3 | Aug 7, 2017 | Merck |
| NCT01661309 | N/A | Mar 31, 2012 | University of West London |
| NCT01039792 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2010 | University of Arkansas, University of California, Davis, University of California, San Francisco |